Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #classaction--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Vaxart, Inc.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Vaxart, Inc.

Shares of this company, which is making a COVID-19 vaccine in pill form, sell for less than half their peak.

Vaxart Stock: Should You Buy the Dip?

What's the Outlook for Vaxart Stock?

New York, New York--(Newsfile Corp. - August 25, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Vaxart, Inc.

Vaxart Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Vaxart, Inc. To Contact The Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Vaxart, Inc. (NASDAQ: VXRT) between June 25, 2020 to July 25, 2020, inclusive (the “Class Period”).

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Vaxart, Inc. – VXRT

BENSALEM, Pa.--(BUSINESS WIRE)---- $VXRT #classaction--INVESTOR ALERT: Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Vaxart, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #VXRT--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #VXRT--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

SAN FRANCISCO--(BUSINESS WIRE)---- $VXRT #NASDAQ--Hagens Berman has filed a class action lawsuit on behalf of investors in Vaxart, Inc. (NASDAQ: VXRT) against the Company and its senior executives

HAGENS BERMAN FILES SECURITIES CLASS ACTION Complaint Against Vaxart (VXRT) and Its Senior Executives

NEW YORK, Aug. 24, 2020 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, is investigating whether Vaxart, Inc.

Scott+Scott Attorneys at Law LLP Announces Investigation into Vaxart, Inc. (VXRT)

Inovio Pharmaceuticals

Novavax

Here's exactly how they could realistically pull it off.

3 Coronavirus Stocks That Could Double by the End of 2020

A potential COVID-19 vaccine in pill form elevated this former penny stock.

Did You Miss Out on the 4900% Gain With Vaxart Stock?

Altimmune

It’s tough to top quadruple-digit growth.

These 3 Surprising Stocks Have Beaten the Market in 2020 -- by a Lot

San Francisco, California--(Newsfile Corp. - August 14, 2020) -  Hagens Berman urges Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Firm's Investigation into Possible Securities Fraud, Encourages Investors with $50K+ Losses and Persons Who May Assist to Contact Its Attorneys Now

SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)---- $VXRT #ClassAction--Shareholder rights law firm Robbins LLP announces it is investigating whether certain officers and directors of Vaxart, Inc. (NASDAQ: VXRT) breached their fiduciary duties and violated federal securities laws.

Shareholder Alert: Robbins LLP Announces It Is Investigating Vaxart, Inc. (VXRT) for Misleading Shareholders

Low-cost prophylactics will be integral to solving the pandemic.

3 Reasons Doctors Will Prefer Vaxart's Coronavirus Vaccine, and 1 Reason They Might Not

OAKLAND, Calif.--(BUSINESS WIRE)---- $VXRT #VXRT--Gibbs Law Group continues to investigate potential legal claims on behalf of Vaxart investors.

Lost Money in Vaxart, Inc.

Sorrento Therapeutics

Major new developments in the race for a COVID-19 vaccine are driving investors to reevaluate their positions.

Why Novavax, Vaxart, Sorrento Therapeutics, and Other Coronavirus Stocks Plummeted Today

The coronavirus vaccine maker is progressing with the clinical trial process.

Why Vaxart Stock Jumped Today

San Francisco, California--(Newsfile Corp. - August 10, 2020) -  Hagens Berman urges Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Firm's Investigation of Possible Securities Fraud, Encourages Investors with $50K+ Losses and Persons Who May Assist to Contact Its Attorneys Now

If approved, the company will soon begin clinical testing of its promising, orally-administered vaccine.

Vaxart Pushes Ahead With IND Filing for COVID-19 Vaccine Candidate

New York, New York--(Newsfile Corp. - August 10, 2020) -  Levi & Korsinsky announces it has commenced an investigation of Vaxart, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vaxart, Inc. - VXRT

MILWAUKEE, Aug. 10, 2020 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating possible securities fraud claims against Vaxart (Nasdaq: VXRT) resulting from inaccurate statements Vaxart made regarding its internal controls, business practices, financial statements and prospects.

Investor Alert: Ademi & O'Reilly, LLP Investigates Possible Securities Fraud of Vaxart, Inc.

SOUTH SAN FRANCISCO, Calif., Aug.  10, 2020  (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its COVID-19 Investigational New Drug (IND) application has been filed with the US Food and Drug Administration (FDA).

Vaxart Announces IND Filed for COVID-19 Vaccine

iBio

These two small-cap biotech stocks have intriguing COVID-19 vaccine candidates.

News for Vaxart Stock (VXRT)